Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.38 |
| ▸ | P2RX2 | Q9UBL9 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401838 | 1.00 | CYP2C9 (0.42) | CYP2C9NR1I2GPR139P2RX3P2RX2 | |
| SCHEMBL19962270 | 0.87 | CYP2C9 (0.48) | CYP2C9NR1I2GPR139P2RX3P2RX2 | |
| SCHEMBL30277283 | 0.87 | CYP2C9 (0.48) | CYP2C9NR1I2GPR139P2RX3P2RX2 | |
| SCHEMBL20581332 | 0.83 | CYP2C9 (0.46) | CYP2C9NR1I2GPR139P2RX3P2RX2 | |
| SCHEMBL20339323 | 0.80 | LMNA (0.42) | LMNAPOLBAPLNR | |
| SCHEMBL16088907 | 0.80 | CYP2C9 (0.55) | CYP2C9NR1I2GPR139P2RX3P2RX2 | |
| SCHEMBL1741864 | 0.79 | GPR139 (0.40) | CYP2C9NR1I2GPR139P2RX3P2RX2 | |
| SCHEMBL20581073 | 0.78 | TRPA1 (0.44) | LMNATRPA1MAPK1APLNR | |
| SCHEMBL20581545 | 0.77 | HTT (0.43) | CYP2C9LMNAPOLBCYP2D6CYP2C19 | |
| SCHEMBL12322204 | 0.77 | P2RX7 (0.43) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12247031-B2 | Cyclobutyl pyrazolopyrimidine PDE9 inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-03-11 | — | — | US | disclosed |
| EP-3893881-B1 | CYCLOBUTYL PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-10-09 | — | — | EP | disclosed |
| EP-3894413-B1 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-3634964-B1 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | MERCK SHARP & DOHME (US) | 2022-02-23 | — | — | EP | disclosed |
| US-20220017525-A1 | CYCLOBUTYL PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-01-20 | — | — | US | disclosed |
| US-20220017526-A1 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-01-20 | — | — | US | disclosed |
| US-11028092-B2 | Substituted pyrazolo[3,4-d]pyrimidines as PDE9 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-06-08 | — | — | US | disclosed |
| US-10934294-B2 | Substituted pyrazolo[3,4-d]pyrimidines as PDE9 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200140445-A1 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-05-07 | — | — | US | disclosed |
| CN-111051308-A | Pyrazolopyrimidine PDE9 inhibitors | 默沙东公司 | 2020-04-21 | — | — | CN | disclosed |
| US-20180354955-A1 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934294-B2 | Substituted pyrazolo[3,4-d]pyrimidines as PDE9 inhibitors | PDE9A, PDE5A, PDE4D | CYP2C9 79/4885NR1I2 2752/4885GPR139 541/4885 |
| US-20200140445-A1 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | PDE9A, PDE5A, PDE2A | CYP2C9 137/4885NR1I2 2191/4885GPR139 771/4885 |
| US-20220017525-A1 | CYCLOBUTYL PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | PDE9A, PDE5A, PDE3B | CYP2C9 211/4885NR1I2 3378/4885GPR139 446/4885 |
| US-11028092-B2 | Substituted pyrazolo[3,4-d]pyrimidines as PDE9 inhibitors | PDE9A, PDE5A, PDE4D | CYP2C9 79/4885NR1I2 2752/4885GPR139 541/4885 |
| US-12247031-B2 | Cyclobutyl pyrazolopyrimidine PDE9 inhibitors | PDE9A, PDE5A, PDE3B | CYP2C9 211/4885NR1I2 3378/4885GPR139 446/4885 |
| US-20220017526-A1 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | PDE9A, PDE5A, PDE12 | CYP2C9 214/4885NR1I2 3527/4885GPR139 661/4885 |
| US-20180354955-A1 | PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | PDE9A, PDE5A, PDE12 | CYP2C9 281/4885NR1I2 3380/4885GPR139 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.